Brian Bello
Psychiatry · Long Beach, CANPI 1902234651
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 406 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,953 and has fallen 92.6% since, to $220 in 2024. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 406 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$1K
- Sunovion Pharmaceuticals Inc.$886
- Otsuka America Pharmaceutical, Inc.$790
- Teva Pharmaceuticals USA, Inc.$744
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$696
- Vanda Pharmaceuticals Inc.$590
- plus $3K from 19 others
What the payments were for
- Food & beverage$7,51699%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 54 | $1,069 |
| Sunovion Pharmaceuticals Inc. | 55 | $886 |
| Otsuka America Pharmaceutical, Inc. | 41 | $790 |
| Teva Pharmaceuticals USA, Inc. | 45 | $744 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $696 |
| Vanda Pharmaceuticals Inc. | 28 | $590 |
| Supernus Pharmaceuticals, Inc. | 23 | $425 |
| Neurocrine Biosciences, Inc. | 21 | $410 |
| Lundbeck LLC | 17 | $334 |
| AbbVie(2 entities) | 19 | $311 |
| Johnson & Johnson | 13 | $304 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $242 |
| Adlon Therapeutics L.p. | 11 | $183 |
| Eisai Inc. | 8 | $139 |
| Corium, LLC | 3 | $65 |
| Neos Therapeutics, LP | 3 | $60 |
| Ironshore Pharmaceuticals Inc. | 3 | $57 |
| Almatica Pharma LLC | 3 | $49 |
| Neuronetics, Inc. | 2 | $47 |
| Indivior Inc. | 2 | $40 |
| Harmony Biosciences LLC | 1 | $39 |
| Bausch Health US, LLC | 1 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Merck | 1 | $21 |
| Noven Therapeutics, LLC | 1 | $18 |
How this compares
$7,567 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Long Beach
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.